AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39768786 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-Based Application for Automatic Detection of Potential Infections
Number of subjects: 0
Study 39768786 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39769201 — intervention group
Group type: EXPERIMENTAL
Intervention: ELA blend
Number of subjects: 0
Study 39769201 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 0
Study 39769389 — intervention group
Group type: EXPERIMENTAL
Intervention: CBA-1205 (afucosylated humanized antibody against DLK1)
Number of subjects: 0
Study 39769389 — intervention group
Group type: EXPERIMENTAL
Intervention: CBA-1205 in combination with lenvatinib
Number of subjects: 0
Study 39769389 — intervention group
Group type: EXPERIMENTAL
Intervention: CBA-1205
Number of subjects: 0
Study 39770444 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ8-THCV after oral administration
Number of subjects: 0
Study 39770444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39770949 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine 2 g/day for 14 weeks
Number of subjects: 49
Study 39770949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 39771009 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group intervention (IG)
Number of subjects: 0
Study 39771009 — intervention group
Group type: COMPARATOR
Intervention: Individual online nutritional counseling (TAU)
Number of subjects: 0
Study 39771516 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Lipid Formulation of Cannabidiol (CBD)
Number of subjects: 0
Study 39771516 — intervention group
Group type: COMPARATOR
Intervention: Control (standard formulation of CBD)
Number of subjects: 0
Study 39772341 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic rectangular rTMS (30 sessions, 3000 pulses per session, 120% resting motor threshold)
Number of subjects: 18
Study 39772341 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic rectangular rTMS (30 sessions, 3000 pulses per session, 120% resting motor threshold)
Number of subjects: 18
Study 39772341 — intervention group
Group type: COMPARATOR
Intervention: Biphasic rectangular rTMS
Number of subjects: 18
Study 39772341 — intervention group
Group type: COMPARATOR
Intervention: Monophasic rectangular rTMS
Number of subjects: 18
Study 39772364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-68-labeled fibroblast activation protein inhibitor
Number of subjects: 40
Study 39772606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial tenecteplase up to 4.5 mg
Number of subjects: 20
Study 39772606 — intervention group
Group type: COMPARATOR
Intervention: Control cohort of MT patients (ALLY MT) not receiving intraarterial tenecteplase
Number of subjects: 20
Study 39772650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fosfomycin
Number of subjects: 0
Study 39772709 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC); unilateral upper limb; cuff pressure 200 mm Hg, twice daily for 7 days
Number of subjects: 547
Study 39772709 — intervention group
Group type: COMPARATOR
Intervention: Sham RIC; cuff pressure 60 mm Hg, same procedure as RIC
Number of subjects: 547
Study 39772802 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 74
Study 39773004 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rituximab
Number of subjects: 50
Study 39773004 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) rituximab
Number of subjects: 50
Study 39773014 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management strategies during asthma attacks
Number of subjects: 30
Study 39773014 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of impending asthma attacks
Number of subjects: 30
Study 39773014 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting β-agonist (SABA) overuse
Number of subjects: 30
Study 39773014 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of asthma attacks
Number of subjects: 30
Study 39773014 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in seeking medical help
Number of subjects: 30
Study 39773112 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD treatment strategies
Number of subjects: 0
Study 39773121 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular profiling techniques including DNA, RNA, and T-cell receptor sequencing on SBA tissue samples.
Number of subjects: 0
Study 39773137 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 27
Study 39773137 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 27
Study 39773172 — intervention group
Group type: EXPERIMENTAL
Intervention: Daraja intervention
Number of subjects: 40
Study 39773172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 39773227 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit
Number of subjects: 99
Study 39773227 — intervention group
Group type: COMPARATOR
Intervention: Access visit
Number of subjects: 99
Study 39773227 — intervention group
Group type: COMPARATOR
Intervention: Home visit vs IRF discharge
Number of subjects: 99
Study 39773251 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention to reduce low-value injury care
Number of subjects: 18
Study 39773255 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic-assisted surgical reduction
Number of subjects: 57
Study 39773406 — intervention group
Group type: EXPERIMENTAL
Intervention: SAC therapists providing effective treatment tools
Number of subjects: 0
Study 39773406 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and supervision for therapists
Number of subjects: 0
Study 39773433 — intervention group
Group type: EXPERIMENTAL
Intervention: PA+Dex (Physical Activity + Dexamethasone 4 mg twice daily for the first 7 days)
Number of subjects: 64
Study 39773433 — intervention group
Group type: COMPARATOR
Intervention: PA+PBO (Physical Activity + Placebo)
Number of subjects: 64
Study 39773460 — intervention group
Group type: EXPERIMENTAL
Intervention: GoldiCare intervention (redistributing weekly workloads)
Number of subjects: 125
Study 39773460 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual work)
Number of subjects: 125
Study 39773460 — intervention group
Group type: EXPERIMENTAL
Intervention: GoldiCare intervention
Number of subjects: 125
Study 39773562 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1,500 mg, intravenously, every four weeks for 26 cycles max) plus tremelimumab (75 mg, intravenously, every four weeks for 4 cycles max) plus metronomic oral vinorelbine (40 mg, every three weeks)
Number of subjects: 31
Study 39773564 — intervention group
Group type: EXPERIMENTAL
Intervention: VB10.16 (3 mg every 3 weeks for 12 weeks, then every 6 weeks) combined with atezolizumab (1,200 mg every 3 weeks for 48 weeks)
Number of subjects: 52
Study 39773564 — intervention group
Group type: EXPERIMENTAL
Intervention: VB10.16 combined with atezolizumab
Number of subjects: 52
Study 39773564 — intervention group
Group type: EXPERIMENTAL
Intervention: VB10.16
Number of subjects: 52
Study 39773694 — intervention group
Group type: EXPERIMENTAL
Intervention: Medisafe app used for 1 month
Number of subjects: 30
Study 39773694 — intervention group
Group type: EXPERIMENTAL
Intervention: Medisafe app reminders
Number of subjects: 30
Study 39773694 — intervention group
Group type: EXPERIMENTAL
Intervention: Medisafe app usability
Number of subjects: 30
Study 39773694 — intervention group
Group type: EXPERIMENTAL
Intervention: Medfriend feature usage
Number of subjects: 30
Study 39773730 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-Fowler position
Number of subjects: 240
Study 39773730 — intervention group
Group type: COMPARATOR
Intervention: Semi sitting position
Number of subjects: 240
Study 39773730 — intervention group
Group type: COMPARATOR
Intervention: Left lateral position
Number of subjects: 240
Study 39773730 — intervention group
Group type: EXPERIMENTAL
Intervention: Various maternal positions during electronic fetal monitoring
Number of subjects: 240
Study 39773759 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT) for 10 weeks
Number of subjects: 72
Study 39773759 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Number of subjects: 72
Study 39773759 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of parental distress and illness worries before and after treatment
Number of subjects: 72
Study 39773784 — intervention group
Group type: EXPERIMENTAL
Intervention: STRATIFYHF artificial intelligence-driven decision support system (DSS)
Number of subjects: 1600
Study 39773784 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based monitoring of clinical characteristics and accelerometry (wrist-worn monitor)
Number of subjects: 1600
Study 39773784 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups and semi-structured interviews with healthcare professionals and study participants
Number of subjects: 1600
Study 39773800 — intervention group
Group type: EXPERIMENTAL
Intervention: Four archetype framework for patients at high risk for opioid use disorder (OUD)
Number of subjects: 40
Study 39773800 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants fitting archetypes 1-4
Number of subjects: 40
Study 39773800 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants fitting archetypes 5-6
Number of subjects: 40
Study 39773800 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in all archetypes
Number of subjects: 40
Study 39773801 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured nurses-led telephone call reminders
Number of subjects: 460
Study 39773801 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visit reminders led by health extension workers
Number of subjects: 460
Study 39773801 — intervention group
Group type: EXPERIMENTAL
Intervention: Application-based automated short message service text reminders
Number of subjects: 460
Study 39773801 — intervention group
Group type: COMPARATOR
Intervention: Standard care (oral follow-up advice and a baseline follow-up card)
Number of subjects: 460
Study 39773822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based meditation and yoga
Number of subjects: 39
Study 39773822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 39773824 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free amphilimus-eluting stent (AES)
Number of subjects: 2107
Study 39773824 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable-polymer everolimus-eluting stent (EES)
Number of subjects: 2107
Study 39773829 — intervention group
Group type: EXPERIMENTAL
Intervention: AID strategy combining angiography and intracoronary testing
Number of subjects: 317
Study 39773829 — intervention group
Group type: EXPERIMENTAL
Intervention: AID strategy
Number of subjects: 317
Study 39773831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg once daily)
Number of subjects: 50
Study 39773831 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (international normalised ratio goal of 2.0-2.5)
Number of subjects: 50
Study 39773831 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs (rivaroxaban and apixaban)
Number of subjects: 50
Study 39773831 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 50
Study 39773838 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux mucosal valvuloplasty (ARMV)
Number of subjects: 74
Study 39773838 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 74
Study 39773848 — intervention group
Group type: EXPERIMENTAL
Intervention: MOON (serious video game) plus standard pharmacological treatment
Number of subjects: 76
Study 39773848 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pharmacological treatment only)
Number of subjects: 76
Study 39773866 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhera CARINAE DH intervention in addition to standard care
Number of subjects: 74
Study 39773866 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 74
Study 39773886 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-ticagrelor
Number of subjects: 5920
Study 39773886 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-clopidogrel
Number of subjects: 5920
Study 39773922 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy for Two-Home Visiting
Number of subjects: 360
Study 39773922 — intervention group
Group type: COMPARATOR
Intervention: Usual home visiting services
Number of subjects: 360
Study 39773950 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch-based PSG
Number of subjects: 206
Study 39773953 — intervention group
Group type: EXPERIMENTAL
Intervention: smCPET
Number of subjects: 43
Study 39773953 — intervention group
Group type: COMPARATOR
Intervention: structured functional capacity surveys
Number of subjects: 43
Study 39773995 — intervention group
Group type: EXPERIMENTAL
Intervention: capsulised intestinal microbiota transplant (IMT)
Number of subjects: 50
Study 39773995 — intervention group
Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 50
Study 39773995 — intervention group
Group type: EXPERIMENTAL
Intervention: not specified
Number of subjects: 50
Study 39774314 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MRI
Number of subjects: 107
Study 39774314 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA sequencing
Number of subjects: 107
Study 39774314 — intervention group
Group type: COMPARATOR
Intervention: Physical examination and laboratory tests
Number of subjects: 107
Study 39774313 — intervention group
Group type: EXPERIMENTAL
Intervention: Xalnesiran 100 mg (group 1)
Number of subjects: 159
Study 39774313 — intervention group
Group type: EXPERIMENTAL
Intervention: Xalnesiran 200 mg (group 2)
Number of subjects: 159
Study 39774313 — intervention group
Group type: EXPERIMENTAL
Intervention: Xalnesiran 200 mg + ruzotolimod 150 mg (group 3)
Number of subjects: 159
Study 39774313 — intervention group
Group type: EXPERIMENTAL
Intervention: Xalnesiran 200 mg + pegylated interferon alfa-2a 180 μg (group 4)
Number of subjects: 159
Study 39774313 — intervention group
Group type: COMPARATOR
Intervention: Nucleoside or nucleotide analogue alone (group 5)
Number of subjects: 159
Study 39774313 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 159
Study 39774400 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen, Initiate, and Maintain (SIM) intervention including healthcare worker training, clinical reminders, and task-sharing strategies
Number of subjects: 0
Study 39774400 — intervention group
Group type: EXPERIMENTAL
Intervention: SIM intervention
Number of subjects: 0
Study 39774509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary tele-rehabilitation (PTR)
Number of subjects: 180
Study 39774509 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (HPR)
Number of subjects: 180
Study 39774509 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 180
Study 39774588 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg per day)
Number of subjects: 589
Study 39774588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study 39774762 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan
Number of subjects: 102
Study 39774762 — intervention group
Group type: COMPARATOR
Intervention: C5 inhibitor (C5i)
Number of subjects: 102
Study 39774828 — intervention group
Group type: EXPERIMENTAL
Intervention: 3x ABVD plus radiotherapy (n=208) in RAPID
Number of subjects: 1288
Study 39774828 — intervention group
Group type: COMPARATOR
Intervention: 3x ABVD alone (n=211) in RAPID
Number of subjects: 1288
Study 39774828 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-4x ABVD plus radiotherapy (n=556) in H10
Number of subjects: 1288
Study 39774828 — intervention group
Group type: COMPARATOR
Intervention: 4-6x ABVD alone (n=303) in H10
Number of subjects: 1288
Study 39774828 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (HRpooled=1.19, 95%CI:1.01-1.35, p=0.005)
Number of subjects: 1288
Study 39774828 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD plus radiotherapy (HRpooled=1.24, 95%CI:1.05-1.46, p=0.009)
Number of subjects: 1288
Study 39774855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C treatment
Number of subjects: 457
Study 39774855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 39774865 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of left ventricular diastolic dysfunction (LVDD)
Number of subjects: 402
Study 39774865 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of LVDD
Number of subjects: 402
Study 39774865 — intervention group
Group type: COMPARATOR
Intervention: No LVDD
Number of subjects: 402
Study 39774967 — intervention group
Group type: EXPERIMENTAL
Intervention: RBI-4000 at 0.1 microgram
Number of subjects: 0
Study 39774967 — intervention group
Group type: EXPERIMENTAL
Intervention: RBI-4000 at 1 microgram
Number of subjects: 0
Study 39774967 — intervention group
Group type: EXPERIMENTAL
Intervention: RBI-4000 at 10 microgram
Number of subjects: 0
Study 39774967 — intervention group
Group type: EXPERIMENTAL
Intervention: RBI-4000 single administration at 1 microgram
Number of subjects: 0
Study 39774967 — intervention group
Group type: EXPERIMENTAL
Intervention: RBI-4000 single administration at 10 microgram
Number of subjects: 0
Study 39774967 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of RBI-4000
Number of subjects: 0
Study 39775037 — intervention group
Group type: EXPERIMENTAL
Intervention: Early TRE
Number of subjects: 197
Study 39775037 — intervention group
Group type: EXPERIMENTAL
Intervention: Late TRE
Number of subjects: 197
Study 39775037 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected TRE
Number of subjects: 197
Study 39775037 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 197
Study 39775039 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt-1:PlGF-based protocol
Number of subjects: 1088
Study 39775039 — intervention group
Group type: COMPARATOR
Intervention: Doppler-based protocol (control)
Number of subjects: 1088
Study 39775041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebroventricular anaerobic dopamine (A-dopamine)
Number of subjects: 9
Study 39775041 — intervention group
Group type: COMPARATOR
Intervention: Optimized oral antiparkinsonian therapy
Number of subjects: 9
Study 39775042 — intervention group
Group type: EXPERIMENTAL
Intervention: Suraxavir marboxil (40 mg)
Number of subjects: 591
Study 39775042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study 39775044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebroventricular B7-H3-targeting CAR T cells
Number of subjects: 21
Study 39775064 — intervention group
Group type: EXPERIMENTAL
Intervention: cipaglucosidase alfa plus miglustat (cipa + mig)
Number of subjects: 0
Study 39775064 — intervention group
Group type: COMPARATOR
Intervention: alglucosidase alfa plus placebo (alg + pbo)
Number of subjects: 0
Study 39775073 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed self-exercises based on electromyography sensor feedback
Number of subjects: 0
Study 39775073 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy alone
Number of subjects: 0
Study 39775195 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning bright light therapy (MBLT); 60-min duration; daily over 28-day duration
Number of subjects: 120
Study 39775195 — intervention group
Group type: COMPARATOR
Intervention: Sham: deactivated negative ion generator; 60-min duration; daily over 28-day duration
Number of subjects: 120
Study 39775226 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical therapy, methotrexate, adalimumab, secukinumab, guselkumab
Number of subjects: 80
Study 39775226 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 39775433 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake-Prone Position (≥ 6 hours/day)
Number of subjects: 728
Study 39775514 — intervention group
Group type: EXPERIMENTAL
Intervention: BIG score
Number of subjects: 563
Study 39775514 — intervention group
Group type: COMPARATOR
Intervention: RTS
Number of subjects: 563
Study 39775514 — intervention group
Group type: COMPARATOR
Intervention: ISS
Number of subjects: 563
Study 39775514 — intervention group
Group type: COMPARATOR
Intervention: GCS
Number of subjects: 563
Study 39775540 — intervention group
Group type: EXPERIMENTAL
Intervention: iTremor ONE device for measuring ocular microtremor (OMT) frequency
Number of subjects: 90
Study 39775540 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of cognitive, motor (using UPDRS-III), and OMT measures
Number of subjects: 90
Study 39775540 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors for assessing balance, gait, and turning
Number of subjects: 90
Study 39775618 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D colonoscopy
Number of subjects: 348
Study 39775618 — intervention group
Group type: COMPARATOR
Intervention: 2D colonoscopy
Number of subjects: 348
Study 39775763 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib maintenance therapy
Number of subjects: 0
Study 39775763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39775763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 0
Study 39775808 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-CR (commercially available software on a tablet, remote monitoring, weekly exercise therapist calls for 3 months)
Number of subjects: 400
Study 39775808 — intervention group
Group type: COMPARATOR
Intervention: Usual care (traditional care at cardiologist's discretion)
Number of subjects: 400
Study 39775812 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD22 CAR T-cell (CAR22) therapy
Number of subjects: 37
Study 39775958 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage operation (AV loop graft and FFMT simultaneously)
Number of subjects: 7
Study 39775958 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage operation
Number of subjects: 7
Study 39775958 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful cases (FFMT with AV loop graft)
Number of subjects: 7
Study 39775962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essential oil inhalation for 20 minutes prior to bed for 5 consecutive days
Number of subjects: 100